Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic Natural Killer Cells in Advanced Metastatic Breast Cancer
NCT00376805Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Apr 2006
- Primary completion
- Sep 2009
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic natural killer cells in breast cancer, sponsored by Masonic Cancer Center. Primary endpoint: Number of Patients Who Had Expansion of Natural Killer Cells at Day 14. Started Apr 2006; status: terminated.
02
Drugs
allogeneic natural killer cells
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00376805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00376805.